Emerging areas of research in the assessment of pharmacokinetics in patients with chronic kidney disease

Drug-Induced Nephrotoxicity: Clinical Impact and Preclinical in Vitro Models

(2014) Ho Yee Tiong et al.   MOLECULAR PHARMACEUTICS

Kidney function assessment and its role in drug development, review and utilization

(2014) Michael A Tortorici et al.   Expert Review of Clinical Pharmacology

Urinary kidney biomarkers for early detection of nephrotoxicity in clinical drug development

(2013) Leonie van Meer et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function

(2013) Janna K. Duong et al.   CLINICAL PHARMACOKINETICS

Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport

(2013) Catherine K. Yeung et al.   KIDNEY INTERNATIONAL

Utility of a physiologically-based pharmacokinetic (PBPK) modeling approach to quantitatively predict a complex drug-drug-disease interaction scenario for rivaroxaban during the drug review process: implications for clinical practice

(2012) Joseph A. Grillo et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Detection and management of nephrotoxicity during drug development

(2012) Dr Mahmoud Loghman-Adham et al.   Expert Opinion On Drug Safety

Evaluation of Exposure Change of Nonrenally Eliminated Drugs in Patients With Chronic Kidney Disease Using Physiologically Based Pharmacokinetic Modeling and Simulation

(2012) Ping Zhao et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Design, Conduct, Analysis, and Interpretation of Clinical Studies in Patients With Impaired Kidney Function

(2012) Michael A. Tortorici et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Regulatory Perspectives on Designing Pharmacokinetic Studies and Optimizing Labeling Recommendations for Patients With Chronic Kidney Disease

(2012) Lei Zhang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Current Understanding of Drug Disposition in Kidney Disease

(2012) Judith Naud et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Biomarkers for Drug-Induced Renal Damage and Nephrotoxicity—An Overview for Applied Toxicology

(2011) Tobias Christian Fuchs et al.   AAPS Journal

Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study

(2011) Ticiana B. Leal et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical Pharmacology Basis of Deriving Dosing Recommendations for Dabigatran in Patients With Severe Renal Impairment

(2011) Sudharshan Hariharan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Dabigatran Etexilate in Atrial Fibrillation Patients With Severe Renal Impairment: Dose Identification Using Pharmacokinetic Modeling and Simulation

(2011) Thorsten Lehr et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Comparative Evaluation of the Cockcroft-Gault Equation and the Modification of Diet in Renal Disease (MDRD) Study Equation for Drug Dosing: An Opinion of the Nephrology Practice and Research Network of the American College of Clinical Pharmacy

(2011) Heather A Nyman et al.   PHARMACOTHERAPY

Modeling and predicting drug pharmacokinetics in patients with renal impairment

(2011) Karen Rowland Yeo et al.   Expert Review of Clinical Pharmacology

Nonrenal Drug Clearance in CKD: Searching for the Path Less Traveled

(2010) Jeremiah D. Momper et al.   ADVANCES IN CHRONIC KIDNEY DISEASE

A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Varenicline for Smoking Cessation

(2010) Hélène M. Faessel et al.   CLINICAL PHARMACOKINETICS

Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium

(2010) Frank Dieterle et al.   NATURE BIOTECHNOLOGY

Renal Vulnerability to Drug Toxicity

(2009) M. A. Perazella   Clinical Journal of the American Society of Nephrology

Population Pharmacokinetics of Orally Administered Duloxetine in Patients

(2009) Evelyn D. Lobo et al.   CLINICAL PHARMACOKINETICS

Drug Development Perspective on Pharmacokinetic Studies of New Drugs in Patients With Renal Impairment

(2009) R L Lalonde et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Novel Biomarkers of Acute Kidney Toxicity

(2009) F M Goodsaid et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates

(2009) Masoud Jamei et al.   Drug Metabolism and Pharmacokinetics

Physiologically based mechanistic modelling to predict complex drug–drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut—The effect of diltiazem on the time-course of exposure to triazolam

(2009) Karen Rowland Yeo et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault Equations for Dosing Antimicrobials

(2009) Elizabeth D Hermsen et al.   PHARMACOTHERAPY

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

(2008) Joseph Gibbons et al.   JOURNAL OF CLINICAL ONCOLOGY